Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
Follow TAK
Takeda Pharmaceutical Co. (TAK) EV/Sales
As of 16 October 2026, Takeda Pharmaceutical Co. (TAK) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from 1.9× (June 2019) to 5.0× (July 2019); the current reading is higher than 80% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 2.8× | 10.89% |
| FY2025 | 2.6× | 3.00% |
| FY2024 | 2.5× | (7.04%) |
| FY2023 | 2.7× | 11.95% |
| FY2022 | 2.4× | (21.48%) |
| FY2021 | 3.0× | 4.24% |
| FY2020 | 2.9× | 27.20% |
| FY2019 | 2.3× | (17.90%) |
| FY2018 | 2.8× | 10.85% |
| FY2017 | 2.5× | 6.87% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | 2.00% |
| Jun 2025 | 2.6× | 7.21% |
| Jun 2024 | 2.4× | (3.51%) |
| Mar 2024 | 2.5× | (0.93%) |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| TAK Takeda Pharmaceutical Co. | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| HLN Haleon PLC Sponsored ADR compare | 3.1× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 3.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| ZTS Zoetis Inc. compare | 4.4× |
| UTHR United Therapeutics Corporation compare | 6.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)